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Abstract
Background
Several pain management guidelines recommend regular urine drug testing (UDT) in patients who are
being treated with chronic opioid analgesic therapy (COAT) to monitor compliance and improve safety.
Guidelines also recommend more frequent testing in patients who are at high risk of adverse events related
to COAT; however, there is no consensus on how to identify high-risk patients or on the testing frequency
that should be used. Using previously described clinical risk factors for UDT results that are inconsistent
with the prescribed COAT, we developed a web-based tool to adjust drug testing frequency in patients
treated with COAT.
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC7203611/?report=printable
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Objective
The objective of this study was to evaluate a risk stratification tool, the UDT Randomizer, to adjust UDT
frequency in patients treated with COAT.
Methods
Patients were stratified using an algorithm based on readily available clinical risk factors into categories of
presumed low, moderate, high, and high+ risk of presenting with UDT results inconsistent with the
prescribed COAT. The algorithm was integrated in a website to facilitate adoption across practice sites. To
test the performance of this algorithm, we performed a retrospective analysis of patients treated with
COAT between June 2016 and June 2017. The primary outcome was compliance with the prescribed
COAT as defined by UDT results consistent with the prescribed COAT.
Results
979 drug tests (867 UDT, 88.6%; 112 oral fluid testing, 11.4%) were performed in 320 patients. An
inconsistent drug test result was registered in 76/979 tests (7.8%). The incidences of inconsistent test
results across the risk tool categories were 7/160 (4.4%) in the low risk category, 32/349 (9.2%) in the
moderate risk category, 28/338 (8.3%) in the high risk category, and 9/132 (6.8%) in the high+ risk
category. Generalized estimating equation analysis demonstrated that the moderate risk (odds ratio (OR)
2.1, 95% CI 0.9-5.0; P=.10), high risk (OR 2.0, 95% CI 0.8-5.0; P=.14), and high risk+ (OR 2.0, 95% CI
0.7-5.6; P=.20) categories were associated with a nonsignificantly increased risk of inconsistency vs the
low risk category.
Conclusions
The developed tool stratified patients during individual visits into risk categories of presenting with drug
testing results inconsistent with the prescribed COAT; the higher risk categories showed nonsignificantly
higher risk compared to the low risk category. Further development of the tool with additional risk factors
in a larger cohort may further clarify and enhance its performance.
Keywords: Urine drug testing, Opioid therapy, Chronic noncancer pain

Introduction
Despite a decline in opioid prescriptions since the height of the opioid crisis in the United States, the use of
opioids for the treatment of chronic pain continues to be common, particularly among primary care
physicians [1]. Chronic opioid analgesic treatment (COAT) may be associated with the development of
opioid use disorders in a subset of patients [2]. To improve the safety of COAT, guidelines recommend a
reduction in opioid dosage for patients prescribed high-dose COAT and monitoring of compliance with the
prescribed COAT regimen [3-8].
Urine drug testing (UDT) has been suggested by several guidelines as a method to observe compliance
with the prescribed therapy in patients treated with COAT [3-8]. Guidelines state that UDT should be
performed at the initiation of opioid treatment [7], at least once a year for patients prescribed COAT [7],
and more often for patients at higher risk of adverse consequences from COAT [6]. However, identification
of high-risk patients with currently available tools may not be reliable [7]. In the absence of effective tools
to identify high-risk patients, some pain physicians have advocated requiring UDT of patients every visit
to increase safety through early detection of inconsistent results [9]. As a result, insurance companies have
noticed a sharp increase in UDT expenditures [10] and have demanded that physicians justify performing
UDT in individual patients to reduce costs [11].
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Several readily available treatment-related factors are known to be associated with an increased risk of
UDT results that are inconsistent with the prescribed COAT. These factors include younger age [12,13],
concomitant use of a benzodiazepine [14], a history of UDT results that are inconsistent with the
prescribed COAT [15], and a higher prescribed daily morphine equivalent dose [13]. We created a webbased clinical tool that uses these factors to adjust the frequency of UDT administered in a chronic
noncancer pain population. The aim of this retrospective study was to validate our stratification algorithm
by comparing the risk allocation of the tool and the results of drug testing over the course of 12 months.

Methods
Inclusion Criteria
This study was conducted in a private interventional pain management institute with 7 specialists across 4
different locations in the New York City area. We retrospectively identified patients without cancer who
had chronic pain that was treated with COAT by reviewing charts between June 1, 2016 and July 1, 2016.
Visits from the 12 months following the initial visit in June 2016 were reviewed for UDT results and for
their consistency with the prescribed opioid therapy. The UDT Randomizer risk categories associated with
each UDT result were also obtained. The UDT Randomizer risk stratification tool was implemented as part
of the standard of clinical care at the institute in March 2016 and had thus been part of normal practice for
some time prior to the inclusion date. Inclusion criteria for the study were age ≥18 years and treatment
with opioids (extended release or immediate release) for more than 12 consecutive weeks at the start of the
retrospective inclusion period. We allowed for a gap period of up to 4 weeks in opioid treatment. The
underlying cause of chronic pain was retrieved from each patient’s medical record, and patients with pain
due to cancer were excluded. The Staten Island University Institutional Review Board approved this study
(study number: 18-0906-SIUHN) and waived the requirement to obtain informed consent for this
retrospective study.
UDT Risk Stratification and Testing Frequency With the UDT Randomizer Tool
The developed stratification tool is depicted in Figure 1. Patients were assigned to a presumed risk group
(low, moderate, high, or high+) based on established risk factors for UDT results inconsistent with the
prescribed COAT. Patients with a history of drug testing inconsistent with the prescribed COAT are
flagged in our electronic medical records, and this flag remains for the duration of treatment in our
practice. Drug testing results inconsistent with the prescribed COAT may serve as an early warning of
adverse outcomes of COAT [9]; therefore, we focused on developing a tool to effectively detect results
inconsistent with the prescribed COAT. The risk allocation was initially based on the daily morphine
equivalent dose prescribed (<40, 40-100, or >100 milligrams). The web tool incorporates a morphine
equivalent dose calculator to facilitate this step. This calculator is based on a previously developed
calculator [16] that was based on American Pain Society guidelines [17] and on several reviews regarding
equianalgesic dosing [18-20]. When 1 or more of the additional risk factors are present (age <45 years,
concomitant benzodiazepine use, or a history of drug testing results inconsistent with the prescribed
COAT), the patient is escalated by 1 risk category (Figure 2).
Patients allocated to the low, moderate, high, and high+ risk categories are randomly requested to undergo
UDT at frequencies of 25%, 33%, 50%, and 60%, respectively. It is important to stress that the chance of
being requested to participate in UDT is thus not random but is rather random with a certain pre-set
probability. We arrived at the testing frequencies through evaluation of the Washington State Agency
Medical Directors’ Group Interagency Guideline and American Academy of Pain Medicine
recommendations on frequency of testing [6,21]. We estimated that we would be able to achieve the
recommended testing frequencies by choosing these set frequencies for the UDT Randomizer.
Primary Outcome
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC7203611/?report=printable
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The primary outcome was compliance with the prescribed opioid therapy. This was assessed by the drug
test results and their consistency with the prescribed opioids over the study period. A drug test result was
considered to be consistent if it was positive for the prescribed opioid or its metabolites and was negative
for other opioids, their metabolites, or illicit substances. A drug test result was considered to be
inconsistent if it was negative for the prescribed opioid or its metabolites or if it was positive for
nonprescribed opioids, their metabolites, or illicit substances. Consistent with recent Centers for Disease
Control and Prevention (CDC) guidance [7], we did not take into account the results of testing for
tetrahydrocannabinol (THC) when determining if a UDT was consistent or inconsistent with the prescribed
therapy.
Drug Testing
Urine toxicology testing was performed by an independent laboratory using liquid chromatography tandem
mass spectrometry (Triple Quad 4500 MD, AB Sciex). If a patient was not able to provide a urine sample,
oral fluid was collected for analysis. Both urine and oral fluid samples were examined for the presence of
prescribed opioids, benzodiazepines, illicit drugs, and their respective metabolites. Chromatographic tests
are specific and are not susceptible to cross-reactions; thus, false positive results are rare [22]. The
detection window is substantially shorter for oral fluid testing vs urine testing (eg, morphine is detectable
2-5 days after use in urine vs 1-36 hours in oral fluid [23]). When a drug is within the detection windows
for both UDT and oral fluid testing, the detection rates are believed to be similar [24].
Data Retrieval
Patient demographics, diagnoses, prescribed medications, and drug testing results were collected
retrospectively from the patients’ medical records. Pain diagnoses were grouped into categories of lower
back pain; cervical pain; arthritis, joint, and muscle pain; and other pain. We retrieved information from all
visits in the 12-month period following the initial included visit in June 2016. Because the data analysis
was conducted at the individual visit level (see the Data and Statistical Analysis section), we included data
regardless of whether the patients remained in our care for the full 12-month period.
Data and Statistical Analysis
Demographics and clinical data are presented as mean (SD) or as n (%). To assess the uptake of the UDT
Randomizer tool, we analyzed how often the tool was used during the first visit for each patient in the
study period. We also assessed how often the tool’s recommendation (Yes or No for UDT) was followed at
that visit. Additionally, we assessed how often UDT testing was ordered without recommendation by the
tool over the course of the entire study period as well as how often the UDT testing recommended by the
tool was ignored by providers over the course of the entire study period. We performed generalized
estimating equations (GEE) analysis with the factors “risk category” and “visit” to assess if the assigned
risk category was related to the consistency of drug testing results with the prescribed COAT using all tests
and risk assignments in the 12-month study period. We used GEE to account for repeated testing in the
same patient. To assess our assumption that there is no association between marijuana use and drug testing
results inconsistent with the prescribed COAT, we performed GEE analysis with THC status on drug
testing as a factor for the consistency of drug testing results with the prescribed COAT as the outcome. The
results of the analyses are presented as odds ratios (ORs) with 95% confidence intervals and the
corresponding P values. Statistical significance was set at P<.05. The software package SPSS version 24
(IBM Corporation) was used for all statistical analyses.

Results
Study Population
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC7203611/?report=printable

4/16

6/29/2021

Development and Performance of a Web-Based Tool to Adjust Urine Toxicology Testing Frequency: Retrospective Study

The study population consisted of 320 patients, of whom 172 (53.8%) were female and 148 (46.3%) were
male (Table 1). Most of the patients’ diagnoses (214/320, 66.9%) were related to spinal pain.
We found that the uptake of the UDT Randomizer tool was high at the first visit in the study period: it was
used in 318/320 patients (99.3%), and its recommendation regarding testing was followed 314 of the 318
times it was used (99.7%). Over the course of the entire 12-month study period, the recommendation of the
tool to test (“Yes”) was followed in 945/964 (98.0%) of visits. Over the 12-month period, 34 tests were
performed contrary to the tool’s guidance to not perform a test.
Primary Outcome: Drug Testing Consistency with the Prescribed COAT
A total of 979 drug tests were performed in the study population over the retrospective 12-month duration
of the study. Of the performed tests, 867/979 (88.6%) were urine drug tests, whereas 112 (11.4%) were
oral fluid tests. All patients provided at least 1 drug test during the follow-up period. Inconsistent drug test
results were registered for 76/979 tests (7.8%) in 52/320 patients (16.3%) during this period. The incidence
of inconsistent test results across the UDT Randomizer tool risk categories varied from 4.4% (low risk) to
9.2% (moderate risk), 8.3% (high risk), and 6.8% (high+ risk; Table 2).
Of the 979 drug tests, 119 (12.2%) were positive for THC, and the positive tests were obtained in 25/320
patients (7.8%). GEE analysis with the risk factors “THC” and “visit” did not demonstrate significantly
higher risk of drug testing inconsistent with the prescribed COAT when a positive test for THC was also
present (OR 1.3, 95% CI 0.6-3.0; P=.48).
Relationships Between the Risk Tool Categories and the Consistency of UDT Results With
the Prescribed COAT
GEE analysis revealed that tests in the moderate, high, and high+ risk categories were associated with a
nonsignificantly higher risk of inconsistency with the prescribed COAT (Table 3).
Because the ORs appeared to be homogenous among the moderate, high, and high+ categories, we
performed a secondary GEE analysis to explore the value of stratifying patients into only 2 risk categories
as a potential next step in the development of the UDT Randomizer tool. We combined the previous
moderate, high, and high+ categories into one high risk category. The performance of this stratification
with regard to the consistency of drug testing with the prescribed opioid therapy was found to be similar to
that of the individual categories in the initial 4-category system (OR of high vs low: 2.0, 95% CI 0.9-4.7;
P=.09).
Additionally, we explored whether a lower cutoff point of 20 daily morphine milligram equivalents
prescribed could improve discrimination by the UDT Randomizer tool. GEE analysis indicated that this
cutoff did not perform better than the previous 2-risk category stratification (OR of high vs low: 1.4, 95%
CI 0.4-4.8; P=.60).

Discussion
Principal Findings
The aim of this study was to assess a risk stratification algorithm we developed to adjust the drug testing
frequency in patients being treated with COAT. The main findings are that the overall inconsistency of
drug testing results with the prescribed COAT was low and that tests in the predefined moderate, high, and
high+ risk categories had a nonsignificantly higher risk of being inconsistent with the prescribed COAT.
Based on available evidence, UDT has been suggested by several guidelines as a method to observe
compliance with the prescribed therapy in patients treated with COAT [3-8]. However, none of these
guidelines provide practical advice on the frequency of testing that should be employed. In the absence of
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC7203611/?report=printable
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such guidance, some pain physicians have adopted the policy of performing UDT virtually every visit to
promote safety and to ensure compliance with regulations, leading to subsequent concerns of
overutilization of UDT [10] and regulatory fines [25]. At the same time, a proportion of physicians
undertest their patients, leading to risk that opioid-related adverse events will not be prevented [26].
Another common approach to testing is a standardized testing interval of every 3-4 months, which allows
patients to prepare for upcoming UDT [15]. Appropriate patient selection for UDT would help limit
overall expenses while maintaining a safe prescription environment. Prior tools that have been developed
to estimate the risk of opioid abuse include the Screener and Opioid Assessment for Patients in PainRevised [27,28], the Current Opioid Misuse Measure [29], the Screening Instrument for Substance Abuse
Potential [30], the Opioid Risk Tool [31] and the Diagnostic, Intractability, Risk, Efficacy [32] tool. These
tools consist of 5-24 questions regarding behavioral factors and family history that impose a greater risk of
opioid use disorders. These tools may require a significant time investment from both the patient and the
pain physician and are dependent on the truthful responses of the patient. In the context of opioid use
disorders, data generally show that such self-reporting is unreliable [33]. The urine toxicology tool we
developed avoids self-reporting, and it incorporates only demographic and treatment-related factors that
are readily available from the patient’s electronic medical record. Because the randomizer uses an
algorithm based on treatment-related factors, the decision whether to perform UDT is not dependent on a
direct decision made by a health care provider, which adds subjectivity to the decision process [34], and
the algorithm returns randomization based solely on probability. Furthermore, taking the provider factor
out of the equation may have a positive effect on the patient-physician relationship, as the physician is
removed from the decision of whether UDT should be performed [7]. The tool can be utilized by any
health care professional assisting the physician in the care of the patient, since all risk factors are readily
available from the medical record. The presented approach avoids a routine schedule for testing (eg, every
3 or 4 months), which may be amenable to manipulation by patients who are prone to opioid misuse
[7,15]. The results of this study indicate that at present, the tool cannot identify patients who are at
significantly higher risk of presenting with testing results inconsistent with their prescribed COAT. There
were nonsignificant differences in inconsistent UDT results between the moderate, high, and high+
categories and the low risk category. It is possible that this study is not sufficiently powered to detect
differences between these groups, given the overall low incidence of inconsistent UDT results. The
homogeneity of the inconsistency rates in the moderate, high, and high+ categories suggests that
development of the tool should focus on combining the current moderate, high, and high+ categories while
incorporating other risk factors to effectively distinguish between higher risk and lower risk patients.
The overall level of observed consistency of the UDT results with the prescribed opioid therapy was high
in the present study (83.7%). This percentage is similar to the percentage reported in a recent study by
Knezevic et al [15], in which 77.2% of the observed study population was found to present with consistent
UDT results. In earlier studies, these rates were found to be much lower (25%-56%) [12,35,36]. These
differences may be due to increased attention to compliance with COAT and UDT among physicians in
more recent studies, differences in the studied populations, or differences in the definition of a “consistent
result” of UDT. In our sample, 25 patients were found to test positive for THC; however, we did not
consider a positive UDT result for THC to be proof of illicit drug use. In the present study, there was no
association between marijuana use and UDT results inconsistent with the prescribed COAT. In the most
recent CDC opioid prescription guidelines, experts noted that it may not be useful to test for THC on UDT
because it is unclear if a positive test for THC should affect patient management [7]. Earlier studies
reported associations between marijuana use in chronic opioid patients and present and future opioid
misuse [37]. Research in twins has suggested that early-onset marijuana use is a risk factor for developing
more severe and pervasive drug use disorders [38]. Currently, fewer people in the United States perceive
marijuana to be harmful compared to a decade ago [39]. Medical marijuana has been introduced in 33
states (including New York and New Jersey), and 11 states allow recreational marijuana use. In states
where marijuana is legalized for medical use, chronic pain is one of the approved indications [40], and
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC7203611/?report=printable
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most persons acquiring medical marijuana do so for pain management [41]. It has been suggested that
medical marijuana legalization reduces overall opioid prescribing and high-risk opioid use [42] by
providing an alternative treatment for chronic pain. It has been suggested that medical marijuana and
recreational marijuana use have opposite effects on overall opioid use and opioid misuse (ie recreational
marijuana increases opioid use and opioid misuse [43]), although a recent analysis of states that legalized
recreational marijuana found no increases in opioid prescriptions [44].
Strengths and Limitations
This was a retrospective study conducted at a single institution. A strength of the study was the prospective
effective implementation of the intervention in the institution prior to the evaluation in this study.
Drug testing results inconsistent with prescribed COAT have been suggested to serve as an early warning
of adverse outcomes of COAT [9]; therefore, we focused on developing a tool to effectively detect
inconsistent results. However, the ultimate relationship between the implementation of UDT in the
management of patients treated with COAT and long-term adverse events of COAT is not well established
at present [7], even though its value in improving safety is assumed in several guidelines [3-8].
Conclusion
The developed tool stratified patients during individual visits into risk categories of presenting with drug
testing results inconsistent with the prescribed COAT; the higher risk categories showed nonsignificantly
higher risk than the low risk category. Further development of this tool with additional risk factors in a
larger cohort may further clarify and enhance its performance.
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Figure 1

Screenshots of the UDT Randomizer tool prior to the selection of risk factors (A) and after the selection of risk
factors (B). The recommendation to perform testing is “Yes” in this case.
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Figure 2

Risk category allocation and the corresponding pre-set chance that the UDT Randomizer tool will request UDT
during a patient visit.
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Table 1
Demographic and treatment characteristics of the patients included in the study.
Characteristic
Age, mean (SD)
Gender, n (%)
Male
Female
Pain diagnosis, n (%)
Lower back
Cervical
Arthritis, joint, and muscle
a
Other
Prescribed opioid dosage in morphine milligram equivalents/day, mean (SD)
Concomitant use of benzodiazepines, n (%)

a

Patients in this category were diagnosed with abdominal pain, endometriosis, pelvic pain, fibromyalgia, phantom
limb pain, or trigeminal neuralgia.
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Table 2
Consistency of drug tests with the prescribed opioid therapy in the 4 risk categories of the UDT
Randomizer tool.
Result

Risk category
Low (n=160)

Moderate (n=349)

Consistent

153 (95.6)

317 (90.8)

Inconsistent

7 (4.4)

32 (9.2)

Negative for prescribed opioid

3 (1.9)

13 (3.7)

Positive for unprescribed opioid

3 (1.9)

15 (4.3)

Positive for illicit drug

1 (0.6)

4 (1.1)

Drug test result, n (%)

Inconsistency of result, n (%)
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Table 3
Generalized estimating equations analysis of the influence of the UDT Randomizer risk category on
the consistency of drug testing with the prescribed opioid therapy.
Risk category

a
OR (95% CI)

Low

Reference

Moderate

2.1 (0.9-5.0)

High

2.0 (0.8-5.0)

High+

2.0 (0.7-5.6)

a

OR: odds ratio
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